2B3-101
Drug timelines are a Plus or Pro feature.
2 regulatory and trial events tracked for 2B3-101, covering 2013-10-29 to 2015-01-22. Get the full timeline:
Most recent: Clinical Trial Update: An Open-label, Phase I/IIa, Dose Escalating Study of 2B3-101 in Patients With Solid Tumors and Brain Metastases or Recurrent Malignant Glioma. [Phase 1, Phase 2]